Sold as Xylo-Pfan, Xylose. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Xylose (sold as Xylo-Pfan, Xylose), first approved Mar 26, 1987, with 0 new uses approved and 0 published complete response letters.
| A Study of GlcNAc on Tear Production in NGLY1-CDDGNGLY1 Deficiency · Eva Morava-Kozicz | Phase 2 | Active, not recruiting | Jun 2, 2022 |
| Response to Different Wheat Genotypes in Not-celiac Wheat SensitivityNon-celiac Wheat Sensitivity · University of Palermo | Not applicable | Recruiting | Jan 19, 2017 |
| Bio-markers of Not-celiac Wheat SensitivityNot-celiac Wheat Sensitivity · University of Palermo | Not applicable | Recruiting | Jan 7, 2013 |
| Mar 26, 1987 | XyloseNDA 18856 · New formulation or manufacturer | Lyne | 0 | Discontinued |
| — | Xylo-PfanNDA 17605 | Savage Labs | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
